Andrew Clarke (@biopatents) 's Twitter Profile
Andrew Clarke

@biopatents

Biotechnology patent attorney specialising in human therapeutics and diagnostics. Partner at Australian IP firm James & Wells and general biotech nerd.

ID: 1370555615546732547

calendar_today13-03-2021 02:01:53

10 Tweet

27 Takipçi

135 Takip Edilen

Donna Farber (@donnafarber3) 's Twitter Profile Photo

Our study, Longitudinal profiling of respiratory and systemic immune responses in severe COVID-19 is online Immunity. Thanks to great collaborators Peter Sims @joshgray12 Thomas Connors @AYatesgroup Microbiology & Immunology at Columbia University Columbia Medicine /1 cell.com/immunity/fullt…

Andrew Clarke (@biopatents) 's Twitter Profile Photo

Back on Twitter after a very lengthy hiatus (head down GSD). Looking forward to sharing biotech insights and baseless opinions. 🤔#HelloWorld #biotech #VentureCapital #nerdy #immunology #Australia

Microba Life Sciences (@microbaofficial) 's Twitter Profile Photo

We’re delighted to announce A/Prof Lutz Krause's appointment as our Chief Scientific Officer, acknowledging his contribution in advancing the precision of our microbiome analysis to drive new discoveries in human health. Read more about his work: microba.com/leadership/#ou…

We’re delighted to announce A/Prof Lutz Krause's appointment as our Chief Scientific Officer, acknowledging his contribution in advancing the precision of our microbiome analysis to drive new discoveries in human health. Read more about his work:  microba.com/leadership/#ou…
Andrew Clarke (@biopatents) 's Twitter Profile Photo

Elegant T cell biology work! Proportions of activated and proliferating CD8+ T cells and MAIT cells are significantly higher in CPI responders, with responder MAIT cells expressing higher level of CXCR4 and producing more granzyme B.

Andrew Clarke (@biopatents) 's Twitter Profile Photo

#AI can outperform humans in giving clinical diagnoses from electronic medical records. No surprise to me... I'm a huge advocate of AI integration across most industries. #future #futureisnow

Andrew Clarke (@biopatents) 's Twitter Profile Photo

Pleased to hear that Celularity Inc. (NASDAQ:CELU) have received fast track status from U.S. FDA for their off-the-shelf allogeneic NK cell therapy for recurrent Glioblastoma multiforme. Huge clinical need. globenewswire.com/news-release/2…